Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

RBC Life Sciences, Inc. was founded in 1988 and is headquartered in Irving, Texas. RBC Life Sciences, Inc., together with its subsidiaries, markets and distributes nutritional supplements and personal care products primarily in the United States, the former Soviet Union, and Canada. It operates in two segments, Nutritional Products and Medical Products. The Nutritional Products segment provides a line of approximately 75 nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life Sciences brand. It markets these products in various categories comprising wellness products, weight loss products, fitness products, and skin care products. This segment markets its products through a network of independent associates, as well as through licensing arrangements with third parties. The Medical Products segment markets a line of approximately 28 wound care products under the MPM Medical brand name.RBC Life Sciences's products include cleansers, dressings, hydrogels, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine, as well as other products, which reduce destruction to skin and tissue caused by radiation, and to reduce pain and itching caused by radiation reactions in the skin and the internal mucosa caused by radiation reactions or reactions to certain cancer medications. Its wound care products are used for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions, as well as to manage pain associated with these wounds in the acute care, long-term care, oncology, and podiatry markets. This segment distributes products to hospitals, nursing homes, clinics, pharmacies, and home health care agencies through medical/surgical supply dealers and pharmaceutical distributors.

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Insys Therapeutics, Inc. company focuses on developing drugs for treating side effects of chemotherapy (such as nausea), as well as therapies for pain management and other central-nervous-system conditions. Its Dronabinol HG candidate, a generic capsule form of Marinol awaiting FDA approval, may treat chemotherapy-induced nausea and vomiting. The firm is also developing inhalation and room-temperature capsule and syrup forms of Dronabinol. In addition, its Fentanyl SL spray, delivered under the tongue for quick absorption, treats pain in cancer patients. All of the company's drug candidates are unique formulations of already-approved therapeutic ingredients.

AutoGenomics was founded in 1999 as Neuron Technologies and applied to go public in 2008. AutoGenomics, Inc. company developed a genetic testing system called INFINITI that scans DNA samples for genetic disorders, infectious diseases, cancer, and pharmacogenetics (a patient's genetic likeliness to have an adverse reaction to a drug). AutoGenomics found about 25 uses for the INFINITI, but only four have been approved by the FDA for diagnostic use -- testing for sensitivity to the popular blood thinner warfarin, screening for the risk of developing cystic fibrosis or cervical cancer (for women with HPV), and testing for a gene that blocks common drugs from working.

Nature's Cure, Inc. company's products pair homeopathic tablets with topical treatments to heal acne and yeast infections. The over-the-counter medicines are manufactured with all-natural ingredients. The acne system is a two-part treatment; the first is a topical medication to combat existing blemishes, and the second is an oral tablet intended to prevent further acne. Its feminine care line offers a variety of yeast infection treatments (topical, oral, 1-day and 3-day) as well as a Vitality line for feminine comfort. The privately-held company was founded by formerProcter & Gamble employee Amy Baker. Its products are sold in retailers like Rite-Aid, nationwide.

Genzyme Pharmaceuticals, a division of leading biotech firm Genzyme, couldn't agree more. The division, at its main production facility in Liestal, Switzerland, makes chemical intermediates and active pharmaceutical ingredients used in the production of a number of drugs, many manufactured by its parent. Its main products include natural and synthetic lipids and amino acid derivatives. It has also partnered with major pharmaceutical companies to develop custom manufacturing of drugs currently in development. Additionally, Genzyme Pharmaceuticals manufactures lipid-based drug delivery systems.

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.